Why Adult RSV Vaccine Advice Changed From Choice to Age and Risk

When the first vaccines for respiratory syncytial virus became available for older adults in 2023, U.S. guidance said adults age 60 or older could receive one dose through shared clinical decision-making. That approach asked a clinician and patient to weigh age, health, preferences, and vaccine characteristics without a universal recommendation for the whole age group.

The policy changed in stages. In 2024, the Advisory Committee on Immunization Practices recommended one dose for every adult age 75 or older and for adults ages 60 to 74 at increased risk of severe RSV disease. In 2025, the risk-based recommendation expanded to ages 50 to 59. Current CDC guidance, updated in February 2026, therefore recommends one dose for all adults 75 and older and adults ages 50 to 74 who have increased risk.

This history is a lesson in how vaccine policy evolves after rollout. Trial efficacy did not suddenly reverse. Decision-makers added real-world effectiveness, safety surveillance, disease-burden estimates, cost-effectiveness, and evidence about whether a broad shared-decision policy reached the people most likely to benefit.

What shared clinical decision-making meant in 2023#

Shared clinical decision-making is a specific ACIP recommendation category. It is not the same as a routine recommendation for everyone in an age group or a risk-based recommendation for people who meet named criteria. It signals that the decision should be individualized because the benefit-harm balance varies or evidence does not support universal use.

In June 2023, ACIP recommended that adults age 60 or older may receive a single dose after such a discussion. The evidence included randomized trials of two vaccines showing protection against RSV lower respiratory tract disease. The committee also considered limited data in the oldest adults and people with substantial immune compromise, questions about duration of protection, cost, and small numbers of inflammatory neurologic events that required surveillance. The recommendation made the vaccines available while acknowledging that uncertainty, and it created a practical challenge at the same time: every eligible person needed a nuanced conversation, and health systems had no simple rule for who should be proactively offered vaccination.

What changed in 2024#

By the next policy review, decision-makers had data from the first season of use. ACIP reviewed real-world effectiveness against medically attended disease and hospitalization, early safety monitoring, uptake, disease burden by age and health status, and economic models.

Risk of severe RSV rises sharply with age. Adults 75 and older account for a high burden of hospitalization and death, making the expected absolute benefit larger. For adults ages 60 to 74, risk varies more. Chronic heart or lung disease, immune compromise, frailty, residence in a nursing home, and other conditions can raise it substantially.

ACIP therefore replaced the open-ended 60-and-older policy with a routine age recommendation at 75 and a risk-based recommendation from 60 through 74. The change made the target population more explicit. It also removed the need to revisit the same general preference conversation for every healthy person in the lower-risk portion of the former age group.

What changed again in 2025#

FDA indications expanded for some adult RSV vaccine products to include younger adults at increased risk. ACIP then reviewed evidence for adults ages 50 to 59. In June 2025, it recommended a single dose for people in that age group who have increased risk of severe RSV disease. The recommendation became official U.S. policy and was incorporated into CDC guidance.

Current guidance groups higher-risk adults from age 50 through 74 together. Adults younger than 50 are not included in the routine CDC adult recommendation as of the research date, even though FDA labeling for particular products may include some higher-risk adults ages 18 to 49. ACIP continues to review evidence for younger groups.

This distinction prevents a common mistake. FDA determines whether a vaccine may be marketed for an indication. ACIP and CDC determine how it should be used in U.S. immunization policy. A broad FDA age range does not automatically create a routine CDC recommendation.

Who counts as higher risk from age 50 through 74#

CDC lists chronic cardiovascular disease, excluding isolated hypertension; chronic lung or respiratory disease; end-stage kidney disease; and certain forms of diabetes with organ damage or particular treatment as examples. Neurologic or neuromuscular disease that impairs airway clearance, chronic liver disease, blood disorders, moderate or severe immune compromise, frailty, and residence in a nursing home can also qualify.

The list includes clinical judgment for other factors a clinician believes increase severe-disease risk. Local epidemiology and community incidence may also matter in some communities. Risk categories are not interchangeable with an online checklist because severity, control, combinations of conditions, and prior vaccination status need review. None of that applies once you reach 75: age alone puts you in the routine group, and no separate qualifying condition is required.

Why age can change the benefit-harm balance#

Vaccine benefit depends partly on how likely you are to meet the severe outcome the vaccine prevents. If hospitalization is uncommon in one group and common in another, similar vaccine effectiveness produces a larger absolute reduction in the higher-risk group.

Age is an imperfect marker. Some adults in their early seventies are frail and medically complex; some adults in their late seventies are robust. Policy uses age because it is objective, easy to implement, and strongly related to severe disease at the population level. The risk-based 50-to-74 category captures some variation below the universal threshold.

An age rule is not a claim that every 75-year-old has identical risk. It is a policy threshold at which offering vaccination to all has a favorable expected balance and is more workable than screening every person for a long list of factors.

What implementation taught the committee#

Shared-decision policies can be appropriate, but they often produce uneven practice. Some clinicians have time and systems for detailed vaccine discussions; others do not. Patients may not know a new vaccine exists. Access, insurance, pharmacy availability, transportation, language, and confidence in vaccines affect uptake.

The 2024 MMWR described low coverage during the first season and unequal uptake across groups. A clearer recommendation can support reminders, standing orders, quality measures, and more consistent conversations. It can also reduce ambiguity about who should be prioritized.

Implementation evidence does not replace clinical evidence. It shows whether a recommendation can deliver the expected benefit in actual care. A policy that is scientifically defensible but too vague to reach high-risk people may need redesign.

Safety evidence and Guillain-Barré syndrome#

Early trials reported a small number of inflammatory neurologic events, and post-authorization surveillance evaluated a possible association with Guillain-Barré syndrome, a rare disorder in which the immune system damages peripheral nerves. Because the event is rare, trials were not large enough to provide a precise estimate.

CDC and FDA continue monitoring. CDC's current safety page states that available evidence supports a benefit that outweighs the potential Guillain-Barré risk for adults 75 and older and higher-risk adults ages 50 to 74. That conclusion is population-specific. It helps explain why policy targets those with the largest expected benefit instead of recommending vaccination universally at younger ages.

Symptoms such as progressive weakness, tingling that spreads, difficulty walking, facial weakness, swallowing difficulty, or breathing difficulty after any recent illness or vaccination require prompt medical assessment. Their presence does not establish the cause.

One dose is not an annual schedule#

Adult RSV vaccination is not currently repeated every season. CDC says that if you have already received one dose you have completed the current recommendation and should not receive another at this time. Studies of duration and revaccination continue, so this may change in the future.

Eligible unvaccinated adults may receive a dose at any time of year, but CDC says late summer and early fall, usually August through October in most of the continental United States, provides the most benefit before typical RSV circulation. Local seasonality can differ. The vaccine can be given at the same visit as other adult vaccines, and whether to coadminister may weigh convenience, the short-term reactions you can expect, and the chance that a vaccine put off is a vaccine never given.

Product choice is separate from eligibility#

Current CDC guidance lists three FDA-licensed adult RSV vaccines and does not prefer one for eligible adults age 50 or older. Product age indications, platform, contraindications, availability, and current labeling still need to be checked.

A prior severe allergic reaction to a component is a contraindication. Moderate or severe acute illness may lead to temporary deferral, while a minor illness often does not. Individual questions belong with a clinician or pharmacist who can review the current product information. This article names no product as better, because policy recommendations can change faster than a static summary can follow them and a commercial comparison would require a separate current review.

How to use the recommendation in a real conversation#

First establish age, prior adult RSV vaccination, and whether a higher-risk condition is present. If you have already had a dose you do not need another under current guidance. If you are 75 or older you qualify without a separate risk factor, and if you are 50 to 74 your risk needs reviewing.

Then discuss expected benefit, common reactions, rare safety uncertainty, timing, other vaccines, and access. The decision should account for the person's questions without recreating the obsolete open-ended rule. A recommendation means clinicians should recommend the vaccine to eligible patients, while informed consent and preference still matter. Finally, verify guidance at the time of vaccination. A policy history is useful for understanding why advice changed; the current CDC page determines what applies now.